BIO Submits Comments to FDA's Draft EA and Preliminary FONSI Regarding the Proposed Field Trial of the OX513A Strain of Aedes aegypti (Ae. aegypti)

May 18 2016
The Biotechnology Innovation Organization (BIO) appreciates this opportunity to provide comments to the U.S. Food and Drug Administration (FDA) on the draft environmental assessment (EA)1 and preliminary finding of no significant impact (FONSI) regarding the proposed field trial of the OX513A strain of Aedes aegypti (Ae. aegypti) developed by Oxitec.

BIO Comments Re: Comments on Sharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors

May 17 2016

Dear Dr. Taichman:


BIO Comments on FDA Natural Food Labeling

May 11 2016
The Biotechnology Innovation Organization (BIO) is pleased to submit these comments to FDA in response to FDA’s request for information on the use of the term “natural” on food labeling (docket no. FDA-2014-N-1207). BIO is the world's largest biotechnology trade association, representing companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than thirty other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.

BIO Submits Comments Re: Medicare Program; Part B Drug Payment Model [CMS-1670-P]

May 9 2016
The Biotechnology Innovation Organization appreciates this opportunity to submit comments on the Centers for Medicare and Medicaid Services’ proposed rule entitled Medicare Program; Part B Drug Payment Model...

Follow-Up on BIO’s Comments in Response to the ICER Value Framework

May 4 2016

BIO’s comments to the USDA on the biomass crop assistance program enacted by the 2008 Farm Bill

Mar 10 2016
Comments are regarding conservation and stewardship requirements, matching payments, establishment costs and annual payments, disclosure of competitively sensitive information, invasiveness determination and review, consistency with existing FSA programs, corporations and publicly traded company participation, eligible materials, and algae.

BIO letter in support of H.R. 5418

Mar 10 2016
To establish a pilot program for educating district court judges on patent related issues.

Cures Acceleration Network: Legislative Text

Mar 10 2016


Small Business Early Stage Investment Program: Legislative Text

Mar 10 2016
The Small Business Early Stage Investment Program would provide matching funds for investment companies who invest in small, high tech companies, including biotech firm.

Diran Makinde, Network Director, NEPAD Biosciences, West Africa Biosciences Network (WABNet), Senegal

Mar 10 2016
Government's role in developing solutions for diseases that disproportionately affect developing countries